Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence
Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, Pfohler C, Staubach P, Treudler R, Wedi B, Magerl M (2018)
Publication Type: Journal article
Publication year: 2018
Journal
Book Volume: 141
Pages Range: 638-649
Journal Issue: 2
DOI: 10.1016/j.jaci.2017.06.032
Abstract
BACKGROUND: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant. OBJECTIVE: From the current published literature, we aimed to determine the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. METHODS: We performed a PubMed search to identify evidence on omalizumab use in the following 9 CIndU subtypes: symptomatic dermographism, cold urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria. RESULTS: Forty-three trials, case studies, case reports, and analyses were identified. Our review indicates that omalizumab has substantial benefits in patients with various CIndUs. The evidence is strongest for symptomatic dermographism, cold urticaria, and solar urticaria. Little/no evidence was available on vibratory angioedema and aquagenic and contact urticaria. Our review supports rapid onset of action demonstrated through early symptom control in most cases, sometimes within 24 hours. Many patients gained complete/partial symptom relief and substantially improved quality of life. Adverse events were generally low, with omalizumab being well tolerated by most patients, including children. CONCLUSIONS: A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. More data from randomized controlled studies are warranted.
Authors with CRIS profile
Additional Organisation(s)
Involved external institutions
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Universität des Saarlandes (UdS)
Germany (DE)
Justus-Liebig-Universität Gießen
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Vivantes - Netzwerk für Gesundheit GmbH
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Germany (DE)
Universität des Saarlandes (UdS)
Germany (DE)
Justus-Liebig-Universität Gießen
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Germany (DE)
Universitätsklinikum Münster
Germany (DE)
Vivantes - Netzwerk für Gesundheit GmbH
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
How to cite
APA:
Maurer, M., Metz, M., Brehler, R., Hillen, U., Jakob, T., Mahler, V.,... Magerl, M. (2018). Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. Journal of Allergy and Clinical Immunology, 141(2), 638-649. https://dx.doi.org/10.1016/j.jaci.2017.06.032
MLA:
Maurer, Marcus, et al. "Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence." Journal of Allergy and Clinical Immunology 141.2 (2018): 638-649.
BibTeX: Download